Trial Profile
Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications HIV-associated lipodystrophy syndrome
- Focus Pharmacodynamics
- 03 May 2014 Status changed from active, no longer recruiting to completed.
- 06 Mar 2014 Primary endpoint 'Magnetic-resonance-imaging-outcomes' has been met.
- 06 Mar 2014 Primary endpoint 'Computed-tomography' has been met.